Q-omics provides the consensus-scored PSMC1 profile across patient tissues and cancer cell-line models. PSMC1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, PSMC1 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, PSMC1 protein abundance shows 27,192 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight HNSC, and GBM as cancer lineages where PSMC1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PSMC1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PSMC1 survival associations across molecular data types. PSMC1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PSMC1 RNA expression–survival associations across cancer types. High PSMC1 expression shows unfavorable associations in HNSC, LUAD, MESO, ACC and BLCA, but favorable associations in KIRC. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for PSMC1 RNA expression.
This table summarizes PSMC1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 7. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PSMC1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PSMC1 shows lower tumor expression in THCA and KICH and higher tumor expression in HNSC, STAD, BLCA and LUSC. The HNSC box plot shows higher PSMC1 RNA expression in tumor versus normal tissue (log2 FC = +1.174, t-test p < 0.001).
This table shows molecular features associated with PSMC1 in patient tissues and cancer cell lines. In patient samples, PSMC1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, PSMC1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Lymphoma.
